Kirsten Axelsen, DLA Piper

Skadden's Rachel Turow explains how MFN reference-pricing exposure is changing the way companies sequence global drug launches and what's at stake for patients outside the U.S.

Leavitt Partners' Julie Tierney and RC Resolve, part of Real Chemistry's Maggie Farley, look at which pharma policies could actually pass — and how companies should talk to stakeholders if pricing or manufacturing becomes a flashpoint heading into the midterms.

As IRA price negotiations reshape the pharmaceutical landscape, leading policy experts unpack what executives need to know now to navigate pricing uncertainty, biosimilar competition, and long-term strategic risk.